Oncolytics Biotech Inc. (ONCY)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.78 |
Market Cap | 62.09M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.25 |
PE Ratio (ttm) | -3.22 |
Forward PE | n/a |
Analyst | Buy |
Ask | 0.82 |
Volume | 1,712,161 |
Avg. Volume (20D) | 1,126,020 |
Open | 0.90 |
Previous Close | 0.88 |
Day's Range | 0.80 - 0.90 |
52-Week Range | 0.71 - 1.53 |
Beta | undefined |
About ONCY
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with ...
Analyst Forecast
According to 2 analyst ratings, the average rating for ONCY stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 396.52% from the latest price.
Why Price Moved
News
2 months ago · seekingalpha.com
Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call TranscriptOncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript